Strimvelis
AXP000211.1 · Viral vector gene therapy
- Platform
- gammaretroviral vector (MoMLV-derived) ex vivo, autologous CD34+ bone marrow cells
- Targets
- ADA
- Originator
- San Raffaele Telethon Institute for Gene Therapy
- Sponsor
- Fondazione Telethon ETS
Names
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- murine leukemia virus (NCBI Taxonomy 11786)
- Strain
- MoMLV-derived gamma-retroviral vector (GSK3336223)
- Replication
- non replicating
- Modifications
- replication-deficient gamma-retroviral vector based on Moloney murine leukaemia virus carrying the human ADA cDNA
- Transgenes
- ADA
- Route
- ex vivo, intravenous
- Carrier
- autologous CD34+ enriched bone marrow cells
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| EMA | EU | 2016-05-26 | approved | Strimvelis | Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) when no suitable HLA-matched related stem cell donor is available | source |
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04959890 | Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy | Unknown | 2021-04-23 | 2024-03-31 | 15 | Severe Combined Immunodeficiency Due to ADA Deficiency | |
| NCT03311074 | Retroviral Insertion Site Methodology Study | Withdrawn | Phase 4 | 2020-06-25 | 2020-07-09 | 0 | Immune System Diseases |
| NCT03232203 | Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs) | Completed | 2018-04-12 | 2021-06-25 | 16 | Severe Combined Immunodeficiency Due to ADA Deficiency | |
| NCT03478670 | Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) | Enrolling by invitation | 2017-05-05 | 2045-12-31 | 50 | Immunologic Deficiency Syndromes | |
| NCT00598481 | ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID | Completed | Phase 2 | 2002-10-02 | 2011-07-10 | 12 | Immunologic Deficiency Syndromes |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38355973 | Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. | Nature medicine | 2024 | cited by trial NCT00598481 |
| PMID 30014500 | Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. | Hepatology (Baltimore, Md.) | 2018 | name in title: Strimvelis |
| PMID 28319446 | Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. | Human gene therapy. Clinical development | 2017 | cited by trial NCT00598481 |
| PMID 27129325 | Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. | Blood | 2016 | cited by trial NCT00598481 |
| PMID 22184407 | Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. | Blood | 2012 | cited by trial NCT00598481 |
| PMID 19179314 | Gene therapy for immunodeficiency due to adenosine deaminase deficiency. | The New England journal of medicine | 2009 | cited by trial NCT00598481 |
| PMID 19633200 | ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. | Blood | 2009 | cited by trial NCT00598481 |
| PMID 19652199 | Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. | Blood | 2009 | cited by trial NCT00598481 |
| PMID 18218852 | Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. | Blood | 2008 | cited by trial NCT00598481 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42648741 | Implementation and use of risk minimization control tools in the EU: A multistakeholder survey. | British journal of clinical pharmacology | 2026 | name in abstract: Strimvelis |
| PMID 37177842 | Clinical applications of gene therapy for rare diseases: A review. | International journal of experimental pathology | 2023 | name in abstract: Strimvelis |
| PMID 34415514 | Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review. | PharmacoEconomics - open | 2022 | name in abstract: Strimvelis |
| PMID 35368231 | Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. | Applied health economics and health policy | 2022 | name in abstract: Strimvelis |
| PMID 32154598 | A systematic review of economic evaluations of advanced therapy medicinal products. | British journal of clinical pharmacology | 2021 | name in abstract: Strimvelis |
| PMID 33309881 | Current Clinical Applications of In Vivo Gene Therapy with AAVs. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | name in abstract: Strimvelis |
| PMID 34790341 | An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models. | Journal of market access & health policy | 2021 | name in abstract: Strimvelis |
| PMID 30334168 | Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation. | PharmacoEconomics - open | 2019 | name in title: Strimvelis |
| PMID 31662152 | Transplantation of gene-modified haematopoietic stem cells: Application and clinical considerations. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde | 2019 | name in abstract: Strimvelis |
| PMID 29159201 | Interactions between Retroviruses and the Host Cell Genome. | Molecular therapy. Methods & clinical development | 2018 | name in abstract: Strimvelis |
| PMID 29491255 | A Novel Approach to the Treatment of Plasma Protein Deficiency: Ex Vivo-Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins. | Chemical & pharmaceutical bulletin | 2018 | name in abstract: Strimvelis |
| PMID 29625577 | Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID. | Orphanet journal of rare diseases | 2018 | name in title: Strimvelis |
| PMID 31282760 | The rapidly evolving state of gene therapy. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 2018 | name in abstract: Strimvelis |
| PMID 27548881 | The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery. | Expert opinion on drug delivery | 2017 | name in abstract: Strimvelis |
| PMID 27762892 | Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View. | Tissue engineering. Part B, Reviews | 2017 | name in abstract: Strimvelis |
| PMID 28148554 | Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis. | EMBO molecular medicine | 2017 | name in title: Strimvelis |
| PMID 28396566 | Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. | EMBO molecular medicine | 2017 | name in abstract: Strimvelis |
| PMID 28560211 | Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. | Frontiers in medicine | 2017 | name in abstract: Strimvelis |
| PMID 28847159 | Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug. | Human gene therapy | 2017 | name in abstract: Strimvelis |
| PMID 27267267 | Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID. | Human gene therapy. Clinical development | 2016 | name in title: Strimvelis |
| PMID 27410196 | Gene therapy for severe combined immune deficiency poised for European approval: If green-lighted, Strimvelis would provide additional treatment option for second most common form of disease. | American journal of medical genetics. Part A | 2016 | name in title: Strimvelis |
| PMID 27419862 | Gene Therapy for "Bubble Boy" Disease. | Cell | 2016 | name in abstract: Strimvelis |
| PMID 27763769 | Standing on the Shoulders of Stem Cell Gene Therapists: History, Hyperbole, and Hope for the Future. | Human gene therapy. Clinical development | 2016 | name in abstract: Strimvelis |
Notes
Autologous CD34+ bone-marrow cells transduced ex vivo with a replication-deficient MoMLV-derived gamma-retroviral vector (GSK3336223) carrying the human ADA cDNA; single intravenous infusion. EU marketing authorisation 2016-05-26, originally GSK, transferred to Orchard Therapeutics and then to Fondazione Telethon; still authorised. Development code GSK2696273.
How to cite
Strimvelis (AXP000211.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000211.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.